

OPTIMA HEALTH PLAN

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process may be delayed.**

Drug Requested: Nuplazid® (pimavanserin)

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy:** _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Maximum allowable daily dose: 2 tablets/day

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ☐ Patient has a diagnosis of Parkinson's disease psychosis

AND

- ☐ Psychotic symptoms have been present for at least one month

AND

- ☐ Psychosis is not due to another cause

AND

- ☐ Patient does not have a history of cardiac arrhythmias or QT prolongation, and the patient does not use another medication concomitantly that prolongs the QT interval

Medication being provided by a Specialty Pharmacy - PropriumRx

Not all drugs may be covered under every Plan.

If a drug is non-formulary on a Plan, documentation of medical necessity will be required

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****

Patient Name: _____

Member Optima #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

DEA OR NPI #: _____

*Approved by Pharmacy and Therapeutics Committee: 10/20/2016

REVISED/UPDATED: 3/31/2017; 8/15/2017; (Reformatted) 6/19/2019; 10/11/2021; 10/27/2021 Reformatted 2/9/2022